168 related articles for article (PubMed ID: 8130209)
1. Unfolding studies of the protease domain of urokinase-type plasminogen activator: the existence of partly folded states and stable subdomains.
Nowak UK; Cooper A; Saunders D; Smith RA; Dobson CM
Biochemistry; 1994 Mar; 33(10):2951-60. PubMed ID: 8130209
[TBL] [Abstract][Full Text] [Related]
2. Domain structure and interactions of recombinant urokinase-type plasminogen activator.
Novokhatny V; Medved L; Mazar A; Marcotte P; Henkin J; Ingham K
J Biol Chem; 1992 Feb; 267(6):3878-85. PubMed ID: 1310986
[TBL] [Abstract][Full Text] [Related]
3. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator.
Spraggon G; Phillips C; Nowak UK; Ponting CP; Saunders D; Dobson CM; Stuart DI; Jones EY
Structure; 1995 Jul; 3(7):681-91. PubMed ID: 8591045
[TBL] [Abstract][Full Text] [Related]
4. Binding of a substrate analogue can induce co-operative structure in the plasmin serine-proteinase domain.
Teuten AJ; Cooper A; Smith RA; Dobson CM
Biochem J; 1993 Jul; 293 ( Pt 2)(Pt 2):567-72. PubMed ID: 8343136
[TBL] [Abstract][Full Text] [Related]
5. Tissue-type plasminogen activator domain-deletion mutant BM 06.022: modular stability, inhibitor binding, and activation cleavage.
Hu CK; Kohnert U; Wilhelm O; Fischer S; Llinás M
Biochemistry; 1994 Oct; 33(39):11760-6. PubMed ID: 7918392
[TBL] [Abstract][Full Text] [Related]
6. Effect of tethered peptidylchloromethylketone inhibitors on thermal stability and domain interactions of urokinase and other serine proteases.
Novokhatny VV; Medved LV; Mazar A; Ingham KC
J Biol Chem; 1993 Aug; 268(23):17211-8. PubMed ID: 8349606
[TBL] [Abstract][Full Text] [Related]
7. Tissue-type plasminogen activator mutants imitating urokinase in the peptide link between kringle and protease domains and at selected sites within the protease domain.
Hinzmann B; Wernicke D; Pfeifer M; Zacharias U; Fischer B; Eisenmenger F; Will H
Eur J Biochem; 1993 Apr; 213(1):437-43. PubMed ID: 8386628
[TBL] [Abstract][Full Text] [Related]
8. Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator.
Hansen AP; Petros AM; Meadows RP; Nettesheim DG; Mazar AP; Olejniczak ET; Xu RX; Pederson TM; Henkin J; Fesik SW
Biochemistry; 1994 Apr; 33(16):4847-64. PubMed ID: 8161544
[TBL] [Abstract][Full Text] [Related]
9. Limited proteolysis of bovine alpha-lactalbumin: isolation and characterization of protein domains.
Polverino de Laureto P; Scaramella E; Frigo M; Wondrich FG; De Filippis V; Zambonin M; Fontana A
Protein Sci; 1999 Nov; 8(11):2290-303. PubMed ID: 10595532
[TBL] [Abstract][Full Text] [Related]
10. Structural investigations of recombinant urokinase growth factor-like domain.
Beloglazova IB; Beabealashvilli RSh; Gursky YG; Bocharov EV; Mineev KS; Parfenova EV; Tkachuk VA
Biochemistry (Mosc); 2013 May; 78(5):517-30. PubMed ID: 23848154
[TBL] [Abstract][Full Text] [Related]
11. NMR studies of the dynamics of the multidomain protein urokinase-type plasminogen activator.
Nowak UK; Li X; Teuten AJ; Smith RA; Dobson CM
Biochemistry; 1993 Jan; 32(1):298-309. PubMed ID: 8380336
[TBL] [Abstract][Full Text] [Related]
12. Reversible independent unfolding of the domains of urokinase monitored by 1H NMR.
Bogusky MJ; Dobson CM; Smith RA
Biochemistry; 1989 Aug; 28(16):6728-35. PubMed ID: 2790026
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor-binding protein activates soluble and receptor-bound single chain urokinase-type plasminogen activator.
Wolf BB; Brown MD
FEBS Lett; 1995 Dec; 376(3):177-80. PubMed ID: 7498536
[TBL] [Abstract][Full Text] [Related]
14. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.
Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC
Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462
[TBL] [Abstract][Full Text] [Related]
15. An efficient system for production of recombinant urokinase-type plasminogen activator.
Tang W; Sun ZY; Pannell R; Gurewich V; Liu JN
Protein Expr Purif; 1997 Dec; 11(3):279-83. PubMed ID: 9425632
[TBL] [Abstract][Full Text] [Related]
16. Domain structure and domain-domain interactions of recombinant tissue plasminogen activator.
Novokhatny VV; Ingham KC; Medved LV
J Biol Chem; 1991 Jul; 266(20):12994-3002. PubMed ID: 1906462
[TBL] [Abstract][Full Text] [Related]
17. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.
Kim KS; Hong YK; Lee Y; Shin JY; Chang SI; Chung SI; Joe Y
Exp Mol Med; 2003 Dec; 35(6):578-85. PubMed ID: 14749538
[TBL] [Abstract][Full Text] [Related]
18. Sequential 1H NMR assignments and secondary structure of the kringle domain from urokinase.
Li X; Smith RA; Dobson CM
Biochemistry; 1992 Oct; 31(40):9562-71. PubMed ID: 1327118
[TBL] [Abstract][Full Text] [Related]
19. Mutagenesis at Pro309 of single-chain urokinase-type plasminogen activator alters its catalytic properties.
Sun Z; Liu JN
Proteins; 2005 Dec; 61(4):870-7. PubMed ID: 16231330
[TBL] [Abstract][Full Text] [Related]
20. Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility.
Behrens MA; Botkjaer KA; Goswami S; Oliveira CL; Jensen JK; Schar CR; Declerck PJ; Peterson CB; Andreasen PA; Pedersen JS
J Mol Biol; 2011 Aug; 411(2):417-29. PubMed ID: 21669207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
